Merck logo

Merck

Last updated January 31, 2026
124
Innovation Areas
5,362
Inventors
47
Collaborations

Azaquinazolinecarboxamide and dicarbonyl-piperidyl derivatives: MerckRecent Research Landscape

Inefficient T-cell activation in the tumor microenvironment limits immunotherapy efficacy, which is addressed by engineering specific fused pyrimidine heterocyclic cores to selectively inhibit HPK1. These precise molecular architectures optimize binding affinity and metabolic stability to enhance anti-tumor immune responses.

What technical problems is Merck addressing in Azaquinazolinecarboxamide and dicarbonyl-piperidyl derivatives?

Aberrant cellular stress signaling

(10)evidences

Suppression of T-cell activation and proliferation by kinase-mediated signaling pathways. Restoring immune surveillance enables the destruction of malignant cells.

Uncontrolled mitotic spindle assembly

(7)evidences

Abnormal kinesin-5 (HSET) activity leads to centrosome clustering failure and mitotic instability in cancer cells. Inhibiting this mechanism restores normal apoptotic pathways in malignant tissues.

Excessive glucosylceramide accumulation

(4)evidences

Unregulated enzymatic activity in metabolic and signaling pathways leads to pathological cell proliferation. Inhibiting these specific protein interactions prevents disease progression in cancer and lysosomal storage disorders.